Imaging the high-affinity, functional state (HA) of dopamine D2 and D3 receptors has been pursued in PET imaging studies of various brain functions. We report further evaluation of 
apomorphine analogs (Finnema et al., 2014; Sromek et al., 2014) and 18 F-aminomethylchroman analogs (Shalgunov et al., 2015a,b) have been reported for imaging dopamine D2 and D3 receptors.
11
C-PHNO is a modified aminotetralin derivative and has high-affinity for D2 and D3 receptor subtypes thus suggesting that PHNO binds to D2-high affinity state (HA) and D3 receptors. Along with binding to the caudateputamen, binding appears to be greater in the globus pallidus indicating a possible D3-preferred binding Tziortzi et al., 2011; Willeit et al., 2006) . Selective agents are needed for both the D2 receptor subtype and D3 receptor subtype. Efforts have been made to identify the D3 receptor binding component of well-known imaging agents, such as 18 F-fallypride (e.g., Mukherjee et al., 2015) . The role of dopamine D3 receptors in addiction is becoming increasingly important and may thus be a target in the treatment of addictive behaviors (Le Foll et al., 2014; Payer et al., 2014) . Efforts are being made to evaluate D3 specific antagonists for treatment of addiction (Mugnaimi et al., 2013) . In addition, there is now an increasing body of evidence to suggest the D3 receptor as a potential therapeutic target for antipakinsonian drugs (Joyce and Millan, 2005) . Studies have demonstrated an up-regulation of the D2 receptor and down-regulation of the D3 receptor in Parkinson's Disease (Levesque et al., 1992; Vuckovic et al., 2010) . Therefore, selective D2 and D3 receptor imaging agents will be more useful in evaluating efficacy of treatment regimens. Development of selective agents have been actively pursued; successful aminotetralin-based, piperazine-based, apomorphine-based compounds have been reported (e.g., Mach et al., 2011; Mukherjee et al., 2000; Shi et al., 2004; Sromek et al., 2014) .
Our previous results with 18 F-fluorinated aminotetralin, 18 F-5-OH-FPPAT showed promising in vivo imaging and selective binding in vitro to the HA-state of the dopamine receptors Shi et al., 2004) . We report two new analogs of 18 F-5-OH-FPPAT, namely 18 F-5-OH-FHXPAT 3 which has an additional carbon extending the distance between the nitrogen and fluorine and 18 F-7-OH-FHXPAT 4, which has the phenolic hydroxyl at the 7-position, an analog of 7-OH-DPAT, known to bind selectively to D3 receptors (7-OH-DPAT is 100 fold more selective for D3R, van Vliet et al., 1996) . Our goal in this article was to evaluate the binding properties of these three agonists, 
| MATERIALS A ND METHODS
All chemicals and solvents were of analytical or HPLC grade from Sigma-Aldrich Chemical Co. and Fisher Scientific. Electrospray mass spectra were obtained on a Model 7250 mass spectrometer (Micromass LCT). Proton NMR spectra were recorded on a Bruker Cryo 500 
The synthesis of 18 F-5-OH-FPPAT was carried out using previously reported methods . F-5-OH-FPPAT, pH in the range of 6-7, was dispensed for in vitro and in vivo studies.
High specific activity fluorine-18 was solubilized using Kryptofix and potassium carbonate. It was evaporated to dryness using anhydrous acetonitrile. The brominated precursor 5 (Figure 2a ; prepared using modifications of procedures described in Shi et al., 2004) was added
(1 mg in 1 mL acetonitrile) and reacted at 968C for 20 min. Following the reaction, any unreacted F-5-OH-FHXPAT 3 was found to be 24.0 min using the solvent of 60% acetonitrile, 0.25% triethylamine in water at a flow rate of 2.0 mL/minute (Figure 2a) . The radiosynthesis was accomplished in 2 hr with a decay corrected overall radiochemical yield of 5-10%. The specific activity of the radiotracer was estimated to be >74 MBq/ nmol.
Partition of 18
F-5-OH-FHXPAT between octanol and 0.066 M phosphate buffered saline, pH 7.4 was carried out in order to estimate lipophilicity as described previously (Shi et al., 1999) . The log P of 18 F-5-OH-FHXPAT was found to be 1.80.
As described above, high specific activity fluorine-18 was reacted with the precursor 2-(N-propyl-N26 0 -bromohexyl)amino-7-tetrahydropyranyltetralin 6, (Figure 2b ; prepared using modifications of procedures described in Shi et al., 2004) . Fluorine-18 was solubilized using Kryptofix and potassium carbonate and evaporated to dryness using anhydrous acetonitrile. Subsequently, the bromo precursor 6 (1 mg in 1 mL with different concentrations of dopamine (final concentrations of 1, 10, and 100 nM).
In vitro effect of isoflurane on the binding of 18 F-5-OH-FHXPAT was evaluated by incubating brain slices in buffer containing 0.1, 1, and 2% isoflurane (v/v). Horizontal brain slices (20 lm thick) were first preincubated for 15 min in the above isoflurane containing buffers, after which incubation was carried out along with 18 F-5-OH-FHXPAT (15 kBq/cc) for 1 hr at 378C. After 60 min, the processing of the slides was carried as described above.
| 18 F-7-OH-FHXPAT
In order to measure total in vitro binding, the preincubated sections were incubated in fresh buffer with Binding was initiated by adding tissue homogenate to the incubation mixture at various times (range between 1 and 120 min) followed by filtration using Brandel filtration apparatus of the incubation mixtures followed by 3 3 5 mL washes with cold buffer. Nonspecific binding was measured using 100 mM of sulpiride. The association rate constant was computed to be M 
| Ex vivo autoradiographic studies of 18 F-5-OH-FHXPAT
Male Sprague-Dawley rats (250-300 g; n 5 3) were fasted 18 hr prior to time of study. On the day of the study, rats were anesthetized using 3.0% isoflurane. 
| Rat PET studies of 18 F-7-OH-FHXPAT
Male Sprague-Dawley rats (250-300 g; n 5 3) were fasted 24 hr prior to time of scan. On the day of the study, rats were anesthetized using 4.0% isoflurane. The rats were then positioned on the scanner bed by placing them on a warm-water circulating heating pad and anesthesia applied using a nose-cone.
18
F-7-OH-FHXPAT (18-37 MBq) was injected intravenously in the tail as 0.3 mL bolus. Isoflurane was reduced and maintained at 2.5% following injection. PET scans were first done with an Inveon dedicated PET scanner (Constantinescu and Mukherjee, 2009 ; Siemens Medical Solutions, Knoxville, TN) followed by CT scans with an Inveon Multimodality CT scanner (large area detector, 10 3 10 cm 2 field-of-view, Siemens Medical Solutions, Knoxville, TN). The two scanners were mechanically docked to each other, which allowed sequential PET and CT scanning. Scans were carried out for 60 min and acquired by the Inveon PET in full list mode. The listmode data were rebinned into 3D sinograms of span 3 and ring difference 79. Random events were subtracted prior to reconstruction. The data was histogrammed into 19 frames and reconstructed using Fourier rebinning and 2D OSEM method with an image matrix of 128 3 128 3 159, resulting in a pixel size of 0.77 mm and a slice thickness of 0.796 mm. Calibration in Bq/cc units was applied using a Ge-68 phantom, which was scanned and reconstructed under the same parameters as the subjects. The CT images were acquired at a binning factor of 4 and were reconstructed using cone-beam reconstruction with a Shepp filter with cutoff at Nyquist frequency resulting in an image matrix of 480 3 480 3 632 and a voxel size of 0.206 mm. All PET data were corrected for random events, scatter and photon attenuation, and for radioactive decay using software provided by scanner manufacturer.
PMOD software was used to process images, extract, and analyze time-activity curves from regions of interest drawn on the dorsal striatum (DStr), ventral striatum (VStr), and cerebellum, which was used as reference for nonspecific binding.
2.6 | Mice PET studies of 18 F-7-OH-FHXPAT 2.6.1 | PET scanning
All mice for this study were bred and genotyped prior to their use in imaging. D2R knock-out (KO) mice were generated at UCI in the Department of Microbiology and Molecular Genetics following an established procedure (Baik et al., 1995) . Mice were housed in individual cages, kept in a climate controlled room (24.48C), with a 12:12-hr light cycle, and had free access to food and water during housing. Subjects were fasted in the imaging room, in a dark quiet place, for 24 hr prior to the scan. Two wild-type (WT) C57BL/6 mice and two D2 KO mice (male, 30-35 g) from the same generation were acquired and used for the in vivo PET scans.
In preparation for the scans, the animals were anesthetized with isoflurane (4% induction) and then maintained under anesthesia throughout the experiments while in the imaging chamber (2.5% maintenance). Animals were injected with the tracer via tail vein outside the scanner and then quickly positioned inside an imaging chamber (M2M technologies) attached to the scanner bed. PET scans were done first with an Inveon dedicated PET scanner (Siemens Medical Solutions, Knoxville, TN) followed by CT scans as described above.
Mice underwent static 18 F-7-OH-FHXPAT (intravenous 2 MBq) scans for 30 min following a 30 min tracer uptake, under anesthesia.
The 30 min uptake period was chosen based on the examination of striatum to cerebellum curves from a rat study, which showed that 18 F-7-OH-FHXPAT reached steady-state after 30 min. Images were reconstructed with Fourier rebinning of 3D data followed by OSEM 2D (16 subsets, 4 iterations, 2 EM iterations). All PET data were corrected for random events, scatter and photon attenuation.
| Data analysis
Processing of reconstructed images and data analysis were performed with PMOD software package (PMOD Technologies). All PET images were co-registered to an MRI brain template (Ma et al., 2008) . The CT images were resliced and manually coregistered via rigid transformations (translations and rotations) to match the template using PMOD Fusion toolbox. A head-and-hat approach was taken for coregistration with using the skull and brain shape features visible in CT and MR template, respectively. The resulting rigid transformation matrix for each subject was subsequently applied to all the PET images to achieve coregistration to the MR template. F-5-OH-FHXPAT, our previously reported 3-step procedure was followed . This included radiolabeling the precursor with fluorine-18, reducing the amide to an amine and removal of the THP group under mild conditions. Radiochemical yields of 18 F-5-OH-FHXPAT were in the 10% range decay corrected. The reduction step using LAH was found to be cumbersome and difficult to automate.
The modified radiosynthesis of FPPAT with about 80% of it displaced in the presence of 100 nM (Figure 3b) .
In vitro association and dissociation experiments in rat brain tissue with 18 F-5-OH-FPPAT were analyzed using kinetic EBDA analysis (Munson and Rodbard, 1980) . All in vitro homogenate binding experiments were carried out at 258C. The observed association rate constant measured from the data shown in Figure 3c was found to be 0.13 min
21
. In the presence of 5 and 50 mM Gpp(NH)p, an 50% reduction in specific binding of 
| 18 F-5-OH-FHXPAT
Similar to the binding of (Figure 5d ).
| Ex vivo distribution studies in rats
Ex vivo autoradiography of coronal sections (20 lm thick) through the striatum showed localization of the radiotracer in the dorsal and ventral To assess displaceability of 18 F-5-OH-FHXPAT in the ex vivo sections, treatment of the sections with buffer solution only, buffer containing 10 mM dopamine, and buffer containing 50 mM Gpp(NH)p had varying effect. In one set, buffer containing 10 mM dopamine, and buffer containing 50 mM Gpp(NH)p were applied only to one-half of the brain and in both the cases there was a reduction in the binding.
To ascertain that this was not simply a displacement effect due to the dilution effect of added buffer, the buffers were added to the entire slice, along with the control buffer with no drug. Dopamine had the greatest displacing effect (striata to cortex ratios before drug was 1.5-1.6, which decreased by >80%), whereas Gpp(NH)p reduced it by >45%, compared with the control buffer. to cerebellum ratios were a little higher, with 2.06 for WT and 1.64 for KO (Figure 8d) . Thus, the VStr had a higher ratio for both mouse types.
| In vivo rat PET studies

| In vitro anesthesia effects
Measurement of effects of isoflurane on the binding of 18 F-5-OH-FHXPAT in vitro revealed a significant reduction in the binding in the striata (Figure 9a ). The striata to cerebellum ratio in the control slice was found to be 11.1 (Figure 9b ). This ratio went down to 7.82 in the presence of 0.1% isoflurane (30% reduction), 3.56 for 1% isoflurane (a reduction of 68%), and 3.03 for 2% isoflurane (a reduction of 73%).
Thus, isoflurane progressively decreased the binding of 
| DISCUSSION
In continuation with our successful PET imaging of dopamine D2-like receptor agonists radiolabeled with carbon-11 (Mukherjee et al., 2000 Shi et al., 1999) , we embarked on the development of fluorine-18 agonist analogs as dopamine D2-like receptor PET imaging agents.
Our initial efforts developed 18 F-5-OH-FPPAT , which showed promising in vitro properties for binding to the high-affinity receptor preferring agent. The 5-hydroxy derivatives were prepared with our reported older method involving 3-steps , whereas the 7-hydroxy derivative was prepared by a newer 2-step method reported here, which provides somewhat higher radiochemical yields and is less cumbersome. The availability of the three radiotracers allowed us to carry out a series of biological experiments to study their binding to the dopamine receptors in vitro, ex vivo and in vivo.
All the three radiotracers, High-affinity state binding was assessed by using Gpp(NH)p as reported by us before (Shi et al., 1999 . It was also shown that Gpp(NH)p decreased or abolished the binding of 3 H-PHNO to the D2 receptors in rat brain slices in vitro (Nobrega and Seeman, 1994) . In vitro autoradiographic binding studies of 2 between striatum and cerebellum . Thus, based on our in vitro and ex vivo observations, it may be surmised that the binding seen in the PET studies is likely to the HA-states of the D2 receptors, perhaps some binding to the D3 receptors and internalized receptors. Because the 7-hydroxy derivatives such as 7-OH-DPAT are more D3-subtype preferring (Mukherjee et al., 2015; van Vliet et al., 1996) , PET studies in the rat with 18 F-7-OH-FHXPAT demonstrated greater localization of the radiotracer in the VStr, a region known to contain relatively more D3 receptors than D2 receptors. At high specific activities it may be assumed that 18 F-7-OH-FHXPAT binding may be predominantly be to D3 subtype, although binding to D2 subtype cannot be ruled out (Gonzalez and Sibley, 1995; Mukherjee et al., 2015) . Interestingly, ratio of ventral striata to cerebellum was 2, similar to that observed with the 5-hydroxy derivatives. Although the initial evaluation is promising, further blocking studies of 18 F-7-OH-FHXPAT with 7-OH-DPAT or other D3 specific drugs need to be performed to completely asses this tracer's specificity to the D3 receptor. These findings are supported by a previous study using autoradiography in mice that showed high 11 C-(1)-PHNO binding in these two regions (Rabiner et al., 2009) . Using the same animal model, we computed the fraction of First, Figure 10 
